Core Viewpoint - The document outlines the management system for the resignation of directors and senior management at Guangxi Liuyao Group Co., Ltd, aiming to ensure stable corporate governance and protect the rights of the company and its shareholders [1]. Summary by Sections General Principles - The system applies to all directors and senior management who resign voluntarily, upon term expiration, or due to dismissal [1]. - The regulations are based on relevant laws, regulations, and the company's articles of association [1]. Resignation Circumstances and Effectiveness - Directors and senior management can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company [3]. - If a director resigns, they must continue to fulfill their duties until a new director is elected if the board's composition falls below the legal minimum [4]. Disclosure and Replacement - The company must disclose the resignation details within two trading days, including the resignation time, reasons, and any ongoing commitments [2]. - A replacement for a resigning director must be completed within 60 days to ensure compliance with legal requirements [2]. Responsibilities and Obligations - Directors and senior management must complete a handover of responsibilities within 30 days after resignation, ensuring business continuity [12]. - They are required to cooperate with any exit audits related to significant decisions made during their tenure [13]. Shareholding Management - Resigning directors and senior management cannot transfer their shares for six months post-resignation [20]. - Any share reduction during their term or within six months post-resignation is limited to 25% of their total shareholding [20]. Final Provisions - The system will be executed in accordance with national laws and regulations, and the board of directors is responsible for its interpretation and revision [22].

第二条 本制度所称信息披露，是指当公司在经营运作中发生或即将发生可能对 公司股票及其衍生品种的交易价格产生较大影响的信息以及证券监管部门要求或公 司主动披露的信息时，根据相关法律、法规及规范性文件等规定，在规定时间内通 过规定的媒体，以规定的方式向社会公众进行公布，并及时报送证券监管部门备案。 第三条 本制度适用于如下人员、机构等信息披露义务人： 第一条 为规范广西柳药集团股份有限公司（以下简称"公司"）的信息披露行 为，加强信息披露事务管理，提高公司信息披露质量，保护投资者合法权益，根据 《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》（以下简称"《股 票上市规则》"）《上海证券交易所上市公司自律监管指引第2号——信息披露事务 管理》等法律、法规、规范性文件和《广西柳药集团股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，结合公司实际情况，制定本制度。 广西柳药集团股份有限公司 信息披露管理制度 (2025年8月修订) 第一章 总 则 （一）公司董事、董事会； （二）公司董事会秘书、证券投资部； （三）公司其他高 ...

广西柳药集团股份有限公司 第二章 会计师事务所执业质量要求 第四条 公司选聘的会计师事务所应当具备以下条件： （一）具备国家行业主管部门和中国证券监督管理委员会规定的开展证券期 货相关业务所需的执业资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； 选聘会计师事务所管理制度 （2025 年 8 月修订） 第一章 总则 第一条 为规范广西柳药集团股份有限公司（以下简称"公司"）选聘（含 续聘、改聘，下同）会计师事务所的相关行为，提高审计工作和财务信息质量， 切实维护股东利益，根据《中华人民共和国公司法》《国有企业、上市公司选聘 会计师事务所管理办法》《广西柳药集团股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，制订本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据有关法律法规要求， 聘任执行年度报告审计业务的会计师事务所对公司财务会计报告、内部控制及相 关信息进行审计，发表审计意见、出具审计报告的行为。 公司选聘会计师事务所开展其他审计业务，视重要性程度可比照本制度执行。 第三条 公司选聘会计师事务所，应当经董事会审计委员会（以下简称"审 计委员会 ...

每经AI快讯，海王生物（SZ 000078，收盘价：2.58元）8月30日发布半年度业绩报告称，2025年上半年 营业收入约143.12亿元，同比减少13.95%；归属于上市公司股东的净利润约3168万元，同比减少 30.23%；基本每股收益0.012元，同比减少30.64%。 （记者 胡玲） 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 ...

Core Viewpoint - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.34 RMB per share, which represents 48.23% of the net profit attributable to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The company reported a net profit of 798,165,020.98 RMB for the first half of 2025 [1]. - The total cash dividend to be distributed is 384,922,717.94 RMB (including tax) [1]. - The distribution will be based on the total share capital registered on the equity distribution record date, excluding repurchased shares [1]. Decision-Making Process - The profit distribution plan was approved during the 27th meeting of the fourth board of directors on August 28, 2025 [2]. - The proposal will be submitted for review at the company's second extraordinary general meeting of shareholders in 2025 [2]. - The supervisory board believes the plan is reasonable and does not harm the interests of the company or its shareholders, especially minority shareholders [2].

Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. reported a steady growth in revenue and profit for the first half of 2025, driven by its innovative transformation and strong performance in both pharmaceutical manufacturing and commercial sectors [2][3]. Company Overview and Key Financial Indicators - The company achieved operating revenue of CNY 141.59 billion, a year-on-year increase of 1.56% [3]. - Total profit reached CNY 6.82 billion, reflecting a significant growth of 41.45% compared to the previous year [3]. - Net profit attributable to shareholders was CNY 4.46 billion, up 51.56% year-on-year [3]. - The company’s net assets amounted to CNY 75.10 billion, a 4.77% increase from the end of the previous year [3]. Business and Operational Highlights - The company focuses on pharmaceutical manufacturing and commercial operations, emphasizing innovation and efficiency [3][4]. - It is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive distribution network covering 25 provinces [3][4]. - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers, enhancing its supply chain capabilities [3][4]. Industry Context - The biopharmaceutical industry in China is recognized as a strategic sector, crucial for national health and security, and is currently undergoing significant structural adjustments [3][4]. - Government policies are aimed at encouraging innovation, optimizing procurement rules, and improving medical insurance payments, which are expected to drive market growth [3][4]. Research and Development - The company invested CNY 1.15 billion in R&D, accounting for 9.44% of its pharmaceutical manufacturing revenue [4][5]. - A total of 56 new drug applications were accepted for clinical trials, including 44 innovative drug projects [4][5]. - The company is advancing several key projects in various therapeutic areas, including hypertension and neurodegenerative diseases [5][6]. Commercial Strategy - The company is enhancing its digital transformation and supply chain efficiency, aiming to provide integrated healthcare solutions [12][13]. - It has launched a new retail strategy that combines traditional and online sales channels, achieving significant growth in e-commerce sales [12][13]. - The company has established a comprehensive import service system, increasing its sales revenue from imported products by 11.7% [12][13]. Corporate Governance and Investor Relations - The company emphasizes long-term stable cash dividends and shareholder returns, having distributed CNY 1.37 billion in dividends for the previous year [15][16]. - It has implemented governance improvements in line with regulatory requirements, including the addition of a female independent director [16][17]. - The company maintains strong communication with investors, ensuring transparency and engagement through various channels [17][18].

| | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 A | 股代码：601607 | 公司简称：上海医药 | | | | | | | | | | | | | H 公司 股代码：02607 | | 公司简称：上海醫藥 | | | | | | | | | | | | | | 上海医药集团股份有限公司 | | | | | | | | | | | | | | | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | | 第一节 重要提示 | | | | | | | | | | | | | | 展规划，投资者应当到 | http://www.sse.com.cn | http://www.hkexnews.hk 网站仔细阅读半年度报告 | | | | | | | | | | | | | 全文。 | | | | | | | | | ...

Group 1: Report Overview - The report is about a research on Shuyu Pingmin in the pharmaceutical commerce industry on August 29, 2025 [1][2] Group 2: Research Participants - Participating research institutions include Northeast Securities, CITIC Securities, China Merchants Securities, Guojin Securities, CITIC Construction, etc [2] Group 3: Company Performance in H1 2025 - The company's cumulative operating income from January to June 2025 was 4.881 billion yuan, a year - on - year increase of 1.30%; the net profit attributable to the parent company's shareholders was 36.2509 million yuan, a year - on - year increase of 49.83% [24] - Affected by industry policies and regulatory environment changes, the company's overall operating income growth slowed down, and the gross profit margin decreased by 1.56% year - on - year. However, the gross profit margin increased by 3.45% quarter - on - quarter compared to H2 2024 [24][25] - The company optimized the store network layout, adjusted the operating area, and optimized lease contract terms. The expense - to - sales ratio was optimized by 1.16% year - on - year [24] - As of the end of June 2025, the company had 9,042 stores in Shandong, Liaoning, Heilongjiang, Fujian, Henan, Gansu and other regions, including 5,072 direct - operated stores and 3,970 franchised stores [25] Group 4: Investor Q&A Impact of Prescription Out - dispensing Policy and Response - In Shandong, the tightening of the national policy has a relatively limited impact on the company. The company's coordinated business in Shandong has achieved a slight increase [25] Measures to Increase Market Share in Shandong - The company uses three core measures: mergers and acquisitions (3 M&A projects with 754 stores in Shandong in H1 2025), franchise upgrade (transforming some franchise stores to quasi - direct - operated franchise mode), and store optimization (closing loss - making stores, adjusting to meet diversified service needs, and piloting 4 "store + outpatient department" model drug - diagnosis stores) [26] Diversified Business Layout - Traditional non - drug categories include health foods, medical devices, and Chinese herbal health teas. Non - traditional categories include the growing health and beauty sector and lifestyle convenience products. The company also has industrial synergy through medical services and cross - border business, and focuses on private domain operations [26] Shandong - Outside M&A Expansion Plan - The company will moderately slow down the pace of M&A outside Shandong, while continuing the M&A plan in Shandong steadily. The current core task is to deepen the local business in Shandong [27] Sales of Self - owned Products - In H1 2025, the sales of self - owned products accounted for about 14%, a year - on - year increase of about 4%. The company expects the proportion to further increase [27] Long - and Medium - Term Online Business Strategy - The company's online business includes B2C, O2O, and private domain operations. B2C maintains stable profitability, O2O is profitable in Shandong and will develop steadily, and private domain operations are the key focus for future development [28] Outlook on Industry Clearance - The number of pharmacies will be gradually streamlined and optimized. With the deepening of the separation of pharmacy and medicine policy, industry concentration will increase, and inefficient pharmacies will be eliminated [29]

Report Information - Reported Company: Jianzhijia [17] - Industry: Pharmaceutical Commerce [2] - Research Date: August 29, 2025 [17] Core Views - The company is facing difficulties in obtaining medical insurance qualifications for newly opened stores, but is actively communicating with regulatory authorities. It is reducing its reliance on medical insurance and expanding non - medical insurance business, with the medical insurance settlement ratio dropping to 40% in H1 2025, a 4% year - on - year decrease [24]. - Through category adjustment, the company has achieved certain results. The proportion of prescription drug revenue structure decreased by 2.31%, while non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26]. Summary by Directory 01. Research Basic Situation - Research Object: Jianzhijia [17] - Industry: Pharmaceutical Commerce [17] - Reception Time: 2025 - 08 - 29 [17] - Reception Personnel: Chairman and General Manager Lan Bo, Financial Controller and Board Secretary Li Heng, Independent Director Guan Yunhong [17] 02. Detailed Research Institutions - Institutions: Investors and others [20] 03. Research Institution Proportion - No relevant content provided 04. Main Content Data - **Category Structure Change**: Newly opened stores in some areas have difficulties in obtaining medical insurance qualifications. The company is actively communicating with regulatory authorities. In H1 2025, the medical insurance settlement ratio was 40%, a 4% year - on - year decrease. The proportion of prescription drug revenue structure decreased by 2.31%, non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - **Online Business**: The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26].

证券日报网讯 8月29日晚间，华人健康发布公告称，公司已于2025年8月29日完成工商变更登记及《公 司章程》的备案手续，并取得合肥市市场监督管理局换发的《营业执照》。变更后注册地址为安徽省合 肥市包河区河北路123号。 （编辑 李家琪） ...